The effect of DIBROMODULCITOL (cas 10318-26-0) on resting and dividing lymphoid cells

Add time:08/04/2019    Source:sciencedirect.com

The effect of DIBROMODULCITOL (cas 10318-26-0) (DBD) on the incorporation of labelled precursors into DNA and RNA fractions of PHA-stimulated human lymphocytes and of P388F lymphoma cells at various stages of their growth was studied. Both cell systems showed sensitivity to the drug within the concentration range of 1–10 μg/ml.When DBD was added before phytohaemagglutinin (PHA), human lymphocytes showed a DNA labelling that was more affected than RNA. In contrast, by adding DBD after PHA, RNA labelling was much more inhibited than DNA. In the latter case, the decrease in DNA labelling occurred only 24 h after drug treatment whereas RNA labelling was decreased 1 h after treatment. Levels of DBD which normally produced 30% inhibition in plating efficiency of P388F lymphoma cells affected uridine-5-T incorporation to a different extent at different stages of growth of the culture. Enhanced RNA labelling occurred in early exponential stage while at later stages of growth, RNA synthesis was depressed.

We also recommend Trading Suppliers and Manufacturers of DIBROMODULCITOL (cas 10318-26-0). Pls Click Website Link as below: cas 10318-26-0 suppliers

Prev:The distribution of bromine content of DIBROMODULCITOL (cas 10318-26-0) in the central nervous system of patients with malignant gliomas
Next:Metabolism and pharmacokinetics of DIBROMODULCITOL (cas 10318-26-0)(DBD, NSC-104800) in man—II. Pharmacokinetics of DBD)